Literature DB >> 33449293

Glucocorticoid signaling and lipid metabolism disturbances in the liver of rats treated with 5α-dihydrotestosterone in an animal model of polycystic ovary syndrome.

Danijela Vojnović Milutinović1, Ana Teofilović1, Nataša Veličković1, Jelena Brkljačić1, Sanja Jelača2, Ana Djordjevic1, Djuro Macut3.   

Abstract

PURPOSE: Polycystic ovary syndrome (PCOS) is a complex reproductive disorder often associated with obesity, insulin resistance, and dyslipidemia. Hormonal changes in PCOS may also include altered glucocorticoid signaling. Our aim was to examine whether alterations in hepatic glucocorticoid signaling are associated with disturbances of glucose and lipid metabolism in animal model of PCOS.
METHODS: Female rats, 3 weeks old, were subcutaneously implanted with 5α-dihydrotestosterone (DHT) or placebo pellets for 90 days to induce PCOS. Expression of 11β-hydroxysteroid dehydrogenase 1 (11βHSD1) and A-ring reductases (5α and 5β), as well as intracellular distribution of glucocorticoid receptor (GR) and expression of its regulated genes were examined in the liver. Proteins of hepatic lipid and carbohydrate metabolism and markers of inflammation were also assessed.
RESULTS: DHT treatment induced increase in body and liver mass, as well as in triglycerides and free fatty acids levels in plasma. Elevation of 11βHSD1 and reduction of 5α-reductase expression was observed together with increased hepatic corticosterone concentration and nuclear GR activation. Induced expression of Krüppel-like factor 15 and decreased expression of genes for proinflammatory cytokines and de novo lipogenesis (DNL) were detected in the liver of DHT-treated rats, while DNL regulators and proinflammatory markers were not changed. However, increased mRNA levels of stearoyl-CoA desaturase and apolipoprotein B were observed in DHT animals.
CONCLUSIONS: DHT treatment stimulated hepatic glucocorticoid prereceptor metabolism through increased corticosterone availability which is associated with enhanced GR activation. This does not affect gluconeogenesis and DNL, but could be linked to stimulated triglyceride synthesis and hypertriglyceridemia.

Entities:  

Keywords:  5α-Dihydrotestosterone; Glucocorticoids; Liver; Polycystic ovary syndrome; Triglycerides

Mesh:

Substances:

Year:  2021        PMID: 33449293     DOI: 10.1007/s12020-020-02600-1

Source DB:  PubMed          Journal:  Endocrine        ISSN: 1355-008X            Impact factor:   3.633


  34 in total

Review 1.  Glucocorticoid hormones and energy homeostasis.

Authors:  Roldan M de Guia; Adam J Rose; Stephan Herzig
Journal:  Horm Mol Biol Clin Investig       Date:  2014-08

Review 2.  Non-alcoholic fatty liver disease in common endocrine disorders.

Authors:  Jonathan M Hazlehurst; Jeremy W Tomlinson
Journal:  Eur J Endocrinol       Date:  2013-06-29       Impact factor: 6.664

Review 3.  The Krüppel-Like Factors and Control of Energy Homeostasis.

Authors:  Paishiun N Hsieh; Liyan Fan; David R Sweet; Mukesh K Jain
Journal:  Endocr Rev       Date:  2019-02-01       Impact factor: 19.871

4.  New mechanisms of glucocorticoid-induced insulin resistance: make no bones about it.

Authors:  Heather A Ferris; C Ronald Kahn
Journal:  J Clin Invest       Date:  2012-10-24       Impact factor: 14.808

Review 5.  Nonalcoholic Fatty Liver Disease in Patients with Polycystic Ovary Syndrome.

Authors:  Djuro Macut; Jelica Bjekić-Macut; Sarantis Livadas; Olivera Stanojlović; Dragan Hrnčić; Aleksandra Rašić-Marković; Danijela V Milutinović; Violeta Mladenović; Zoran Andrić
Journal:  Curr Pharm Des       Date:  2018       Impact factor: 3.116

6.  Expression of 11β-hydroxysteroid dehydrogenase type 1 in visceral and subcutaneous adipose tissues of patients with polycystic ovary syndrome is associated with adiposity.

Authors:  Barbara Mlinar; Janja Marc; Mojca Jensterle; Eda Vrtačnik Bokal; Aleš Jerin; Marija Pfeifer
Journal:  J Steroid Biochem Mol Biol       Date:  2010-12-13       Impact factor: 4.292

7.  Altered cortisol metabolism in polycystic ovary syndrome: insulin enhances 5alpha-reduction but not the elevated adrenal steroid production rates.

Authors:  Tasoula Tsilchorozidou; John W Honour; Gerard S Conway
Journal:  J Clin Endocrinol Metab       Date:  2003-12       Impact factor: 5.958

8.  Polycystic ovary syndrome with hyperandrogenism is characterized by an increased risk of hepatic steatosis compared to nonhyperandrogenic PCOS phenotypes and healthy controls, independent of obesity and insulin resistance.

Authors:  Helen Jones; Victoria S Sprung; Christopher J A Pugh; Christina Daousi; Andrew Irwin; Nabil Aziz; Valerie L Adams; E Louise Thomas; Jimmy D Bell; Graham J Kemp; Daniel J Cuthbertson
Journal:  J Clin Endocrinol Metab       Date:  2012-07-26       Impact factor: 5.958

Review 9.  The polycystic ovary syndrome: a position statement from the European Society of Endocrinology.

Authors:  Gerard Conway; Didier Dewailly; Evanthia Diamanti-Kandarakis; Héctor F Escobar-Morreale; Stephen Franks; Alessandra Gambineri; Fahrettin Kelestimur; Djuro Macut; Dragan Micic; Renato Pasquali; Marija Pfeifer; Duarte Pignatelli; Michel Pugeat; Bulent O Yildiz
Journal:  Eur J Endocrinol       Date:  2014-05-21       Impact factor: 6.664

10.  Regulation of triglyceride metabolism by glucocorticoid receptor.

Authors:  Jen-Chywan Wang; Nora E Gray; Taiyi Kuo; Charles A Harris
Journal:  Cell Biosci       Date:  2012-05-28       Impact factor: 7.133

View more
  1 in total

Review 1.  Thrombosis and Anticoagulation Therapy in Systemic Lupus Erythematosus.

Authors:  Wenjun Yuan; Fengjun Guan
Journal:  Autoimmune Dis       Date:  2022-06-27
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.